Skip to main content

Is Metrnl an Adipokine İnvolved in the Anti-inflammatory Response to Acute Exacerbations of COPD?

Lung volume 198, pages 307–314 (2020)Cite this article

Abstract

Purpose

Chronic obstructive pulmonary disease (COPD) is a common lung disease characterized by airflow limitation and systemic inflammation. Recently, there has been growing interest in adipose tissue-mediated inflammation in the pathogenesis of COPD. The aim of our study was to determine the relationships between a new adipocytokine, meteorin-like protein (Metrnl), and acute exacerbations of COPD, smoking, and comorbidities.

Materials and Methods

The study included 313 patients aged 40–65 years in four groups: Group 1: ex-smokers (≥ 20 pack-years) with COPD hospitalized for COPD exacerbation (n = 133), Group 2: current-smokers (≥ 20 pack-years) without COPD (n = 60), Group 3: ex-smokers (≥ 20 pack-years) without COPD (n = 60), and Group 4: never-smokers without COPD (n = 60). Peripheral venous blood samples (5 cc) were collected from all participants. Plasma Metrnl levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kit.

Results

Mean Metrnl levels were 28.45 ± 11.27 ng/ml in Group 1, 24.34 ± 4.38 ng/ml in Group 2, 18.84 ± 3.8 ng/ml in Group 3, and 19.44 ± 3.92 ng/ml in Group 4. Group 1 had significantly higher mean Metrnl level compared to the other groups (p = 0.006, p = 0.001, p = 0.001). Metrnl level was also significantly higher in Group 2 when compared with Groups 3 and 4 (p = 0.001, p = 0.005). Group 1 patients with diabetes mellitus and coronary artery disease showed significantly lower Metrnl levels compared to other patients in the group (p = 0.001, p = 0.001).

Conclusion

The high Metrnl level in COPD exacerbations and active smoking may be important in balancing the inflammatory response. However, plasma Metrnl levels were found to be lower in COPD patients with comorbidities.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Celli BR (2008) Update on the management of COPD. Chest 133(6):1451–1462

    Article  Google Scholar 

  2. Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E (2014) Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediat Inflamm 2014:232167

    Article  Google Scholar 

  3. Wang K, Li F, Wang C, Deng Y, Cao Z, Cui Y, Xu K, Lin P, Sun Y (2019) Serum levels of meteorin-like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance. Med Sci Monit 25:2337

    CAS  Article  Google Scholar 

  4. Ushach I, Arrevillaga-Boni G, Heller GN, Pone E, Hernandez-Ruiz M, Catalan-Dibene J, Hevezi P, Zlotnik A (2018) Meteorin-like/Meteorin-β is a novel immunoregulatory cytokine associated with inflammation. J Immunol 201(12):3669–3676

    CAS  Article  Google Scholar 

  5. Chung HS, Hwang SY, Choi JH, Lee HJ, Kim NH, Yoo HJ, Seo J-A, Kim SG, Kim NH, Baik SH (2018) Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract 136:100–107

    CAS  Article  Google Scholar 

  6. Dadmanesh M, Aghajani H, Fadaei R, Ghorban K (2018) Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS ONE ONE 13(9):e0204180

    Article  Google Scholar 

  7. Liu ZX, Ji HH, Yao MP, Wang L, Wang Y, Zhou P, Liu Y, Zheng XF, He HW, Wang LS (2019) Serum Metrnl is associated with the presence and severity of coronary artery disease. J Cell Mol Med 23(1):271–280

    CAS  Article  Google Scholar 

  8. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, Yang IA (2016) Acute exacerbation of COPD. Respirology 21(7):1152–1165

    Article  Google Scholar 

  9. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DM, Han M (2019) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 53(5):1900164

    CAS  Article  Google Scholar 

  10. Yamasaki K, Eeden SFV (2018) Lung macrophage phenotypes and functional responses: role in the pathogenesis of COPD. Int J Mol Sci 19(2):582

    Article  Google Scholar 

  11. Kopf M, Schneider C, Nobs SP (2015) The development and function of lung-resident macrophages and dendritic cells. Nat Immunol 16(1):36

    CAS  Article  Google Scholar 

  12. Hu Y, Huo S, Zeng X, Bao H, Liu X (2019) Effect of actin-related protein 2–3 complex on phagocytosis defect of alveolar macrophages in a mouse model of chronic obstructive pulmonary disease. Zhonghua yi xue za zhi 99(30):2355–2361

    CAS  PubMed  Google Scholar 

  13. Novak ML, Koh TJ (2013) Macrophage phenotypes during tissue repair. J Leukoc Biol 93(6):875–881

    CAS  Article  Google Scholar 

  14. Zheng S-l, Li Z-y, Song J, Liu J-m, Miao C-y (2016) Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin 37(5):571

    CAS  Article  Google Scholar 

  15. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, Meurice J-C, Morel H, Person-Tacnet C, Leroyer C (2013) Comorbidities of COPD. Eur Respir Rev 22(130):454–475

    Article  Google Scholar 

  16. El-Ashmawy HM, Selim FO, Hosny TA, Almassry HN (2019) Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract 150:57–63

    CAS  Article  Google Scholar 

  17. Terzano C, Colamesta V, Unim B, Romani S, Meneghini A, Volpe G, La Torre G (2017) Chronic obstructive pulmonary disease (COPD) exacerbation: impact of comorbidities on length and costs during hospitalization. Eur Rev Med Pharmacol Sci 21(16):3680–3689

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Depertmant of Pulmonary Diseases, Health Sciences University Erzurum Regional Education and Research Hospital, 25240, Yakutiye, Erzurum, Turkey

    Buğra Kerget

  2. Depertmant of Pulmonary Diseases, Ağrı State Hospital, Ağrı, Turkey

    Dursun Erol Afşin

  3. Depertmant of Infection Diseases and Clinical Microbiology, Health Sciences University Erzurum Regional Education and Research Hospital, Erzurum, Turkey

    Ferhan Kerget

  4. Department of Biochemistry, Ataturk University School of Medicine, 25240, Erzurum, Turkey

    Seda Aşkın

  5. Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Erzurum, Turkey

    Metin Akgün

Authors
  1. Buğra Kerget
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dursun Erol Afşin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferhan Kerget
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seda Aşkın
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Metin Akgün
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Buğra Kerget.

Ethics declarations

Conflict of interest

The authors received no financial support for the research and/or authorship of this article. The authors declare that they have no conflict of interest to the publication of this article.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kerget, B., Afşin, D.E., Kerget, F. et al. Is Metrnl an Adipokine İnvolved in the Anti-inflammatory Response to Acute Exacerbations of COPD?. Lung 198, 307–314 (2020). https://doi.org/10.1007/s00408-020-00327-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-020-00327-4

Keywords

  • COPD
  • Coronary artery disease
  • Diabetes mellitus
  • Elisa
  • Metrnl